Healio Minute Podcast, Lung Cancer Edition: Top Headlines - Week of January 15, 2024
Click Here to Manage Email Alerts
In this edition, FDA places hold on cell therapy trial after patient death, selpercatinib delivers superior outcomes and more.
Read the full coverage here:
FDA places hold on trial of cell therapy for lung cancer after patient death
Selpercatinib delivers superior outcomes, may ‘reduce the burden of NSCLC’
First-line immunotherapy benefits patients of all races with NSCLC equally
Never-smoker lung cancer survivors require targeted surveillance
Cemiplimab plus chemotherapy improves outcomes in metastatic NSCLC
References:
Baramidze A, et al. Abstract 1495P. Presented at: European Society for Medical Oncology Congress; Oct. 20-24, 2023; Madrid.
Choi E, et al. JAMA Netw. Open. 2023;doi:10.1001/jamanetworkopen.2023.43278.
Lee M, et al. J. Natl Compr Canc Netw. 2023;doi:10.6004/jnccn.2023.7064
Zhou C, et al. N Engl J Med. 2023;doi:10.1056.NEJMoa2309457.
Collapse